Photo taken from: Yüksel Ürün/X
Jan 6, 2024, 23:03
Yüksel Ürün: BEATcc Trial
Yüksel Ürün, Professor at the Department of Medical Oncology, Ankara University School of Medicine, recently posted on X/Twitter:
“BEATcc Trial:
– Dual primary endpoints: Progression-free survival & overall survival.
– Improved outcomes: Atezolizumab group showed better PFS (13.7 vs 10.4 months) & OS (32.1 vs 22.8 months).
– Atezo/Beva/chemo could redefine first-line treatment for metastatic/recurrent cervical cancer.
Reminder: The most effective way to prevent cervical cancer is screening and HPV vaccination.”
Read further.
Source: Yüksel Ürün/X